CAPR News and Press, Capricor Therapeutics Inc. From 01/19/21

Capricor Therapeutics ([[CAPR]] +10.8%) announces findings from collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency.Capricor's lead candida...

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Capricor Therape u tics, Inc. (NASDAQ: CAPR), a cli...

Clinical-stage biotechnology company Capricor Therapeutics (CAPR) and Lonza have entered into an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells ((CDC)) technology for the treatment of Duchenne Muscular Dystrophy ((DMD)) a...

—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to expand Capricor’s manufacturing capacity fo...

Lion Group Holding (LGHL) +142%.SCWorx (WORX) +55%.Future FinTech Group (FTFT) +41%.Optical Cable Corporation (OCC) +29%.ZW Data Action Technologies (CNET) +29%.Jaguar Health (JAGX) +25%.Merus N.V. (MRUS) +24% after FDA grants Fast Track designation to it's Zenocutuzumab.Ideanomics ...

Click here to read the previous top NASDAQ biotech stocks article. It’s been a stellar year for the NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ), which started at 3,763.05 points in January and reached a high of 4,811.03 points on December 15. While the inde...

LOS ANGELES, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therape u tics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention...

The first two patients have been dosed in Capricor Therapeutics' (CAPR) Phase 2 study evaluating intravenous infusion of CAP-1002 – its lead clinical asset - using allogeneic cardiosphere-derived cells ((CDC)) technology as a treatment option for patients with COVID-19.The study will e...

- Data Expected Second Quarter 2021 - - The INSPIRE Trial Is Designed t o Assess t he Ability o f CAP-1002 t o Modulate t he Cytokine Storm Associated With Severe COVID-19 - LOS ANGELES, Nov. 24, 2020 (GLO...

Capricor Therapeutics, Inc. (CAPR) Q3 2020 Earnings Conference Call November 12, 2020 04:30 pm ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - President, Chief Executive Officer and Director Steve Gould - Executive Consultant Conference Call Participants Em...